QUEBEC CITY, June 10 /CNW/ - Medicago Inc. (TSX-V:MDG) (the "Company"), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Andy Sheldon, President and CEO, will present at the World Vaccine Congress Asia 2010. The conference is being held at Grand Hyatt, Singapore, from June 8-11, 2010.
Mr. Sheldon's presentation, entitled "Strategies to face the challenge of delivering broadly effective pandemic vaccines at the right place and the right moment," will discuss how Medicago's plant-based manufacturing technology could deliver an affordable and effective vaccine just one month after the identification of the genetic sequence from an emerging pandemic strain. The presentation highlights the ability of Medicago's technology to offer cost-effective strategies for global vaccine delivery in relation with lessons learned from the 2009 pandemic. Mr. Sheldon will also review clinical data from its plant-derived VLP-based H5N1 vaccine.
World Vaccine Congress Asia 2010 is a meeting where vaccine buyers and sellers, health authorities, financing institutions, regulators, vaccine producers and manufacturers, technology providers and other stakeholders come together to discuss industry trend, market and partnership opportunities, new vaccines and new technology innovations across Asia.
Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with Medicago's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Medicago or its management. The forward-looking statements are not historical facts, but reflect Medicago's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including the matters discussed under "Risks Factors and Uncertainties" in Medicago's Annual Information Form filed on March 24, 2010 with the regulatory authorities. Medicago assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements
SOURCE Medicago Inc.
For further information: For further information: Medicago, Inc., Andy Sheldon, President and CEO, (418) 658-9393; Medicago Inc., Christina Cameron, Manager, Investor Relations, (647) 962-9393